STAT+: Roche to Launch Another Elevidys Trial, with Eyes on European Approval

Why It Matters

Securing EU approval would give Roche its first gene‑therapy foothold in the lucrative DMD market, expanding patient access and diversifying the company’s biotech revenue stream.

Key Takeaways

• Roche initiates new Phase 3 Elevidys trial with 100 early‑stage DMD patients
• Study spans 72 weeks, comparing gene therapy against placebo
• Aim: produce data for EMA resubmission after prior negative review
• European approval would expand market beyond US, boosting Roche's biotech portfolio

Pulse Analysis

Duchenne muscular dystrophy (DMD) remains one of the most severe pediatric neuromuscular disorders, affecting roughly one in 3,500 male births worldwide. Gene‑therapy approaches like Elevidys aim to deliver a functional copy of the dystrophin gene, addressing the disease’s root cause rather than merely managing symptoms. While the United States granted Elevidys accelerated approval in 2023, the therapy’s long‑term efficacy and safety profile continue to be scrutinized, especially as payers evaluate cost‑effectiveness for a treatment priced in the high‑hundreds of thousands of dollars per patient.

In Europe, the European Medicines Agency (EMA) issued a negative opinion in 2025, citing insufficient evidence of durable clinical benefit. Roche’s decision to launch a fresh Phase 3 trial reflects a strategic pivot toward generating the robust, long‑term data the EMA demands. By enrolling about 100 boys at early disease stages and extending observation to 72 weeks, the study seeks to demonstrate sustained functional gains and safety signals that were previously lacking. The trial’s placebo‑controlled design also aligns with regulatory expectations for clear comparative outcomes, potentially smoothing the path for a future resubmission.

If the trial meets its endpoints, Roche could secure the first EU approval for a DMD gene‑therapy, unlocking a market estimated at €1 billion (≈ $1.1 billion) annually. Such a win would not only diversify Roche’s oncology‑heavy portfolio but also position the company as a leader in rare‑disease gene‑therapy development. Moreover, a positive European decision could influence other jurisdictions, prompting parallel submissions in Japan and Canada, and reinforcing the commercial viability of high‑cost, one‑time curative treatments.